Journal of Hematology & Oncology (Apr 2023)
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
- Francesco Marchesi,
- Jon Salmanton-García,
- Caterina Buquicchio,
- Federico Itri,
- Caroline Besson,
- Julio Dávila-Valls,
- Sonia Martín-Pérez,
- Luana Fianchi,
- Laman Rahimli,
- Giuseppe Tarantini,
- Federica Irene Grifoni,
- Mariarita Sciume,
- Jorge Labrador,
- Raul Cordoba,
- Alberto López-García,
- Nicola S. Fracchiolla,
- Francesca Farina,
- Emanuele Ammatuna,
- Antonella Cingolani,
- Daniel García-Bordallo,
- Stefanie K. Gräfe,
- Yavuz M. Bilgin,
- Michelina Dargenio,
- Tomás José González-López,
- Anna Guidetti,
- Tobias Lahmer,
- Esperanza Lavilla-Rubira,
- Gustavo-Adolfo Méndez,
- Lucia Prezioso,
- Martin Schönlein,
- Jaap Van Doesum,
- Dominik Wolf,
- Ditte Stampe Hersby,
- Ferenc Magyari,
- Jens Van Praet,
- Verena Petzer,
- Carlo Tascini,
- Iker Falces-Romero,
- Andreas Glenthøj,
- Oliver A. Cornely,
- Livio Pagano
Affiliations
- Francesco Marchesi
- Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute
- Jon Salmanton-García
- Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne
- Caterina Buquicchio
- Ematologia Con Trapianto
- Federico Itri
- San Luigi Gonzaga Hospital - Orbassano
- Caroline Besson
- Centre Hospitalier de Versailles
- Julio Dávila-Valls
- Hospital Nuestra Señora de Sonsoles
- Sonia Martín-Pérez
- Hospital Nuestra Señora de Sonsoles
- Luana Fianchi
- Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS
- Laman Rahimli
- Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne
- Giuseppe Tarantini
- Ematologia Con Trapianto
- Federica Irene Grifoni
- Hematology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- Mariarita Sciume
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- Jorge Labrador
- Department of Hematology, Research Unit, Hospital Universitario de Burgos
- Raul Cordoba
- Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD
- Alberto López-García
- Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD
- Nicola S. Fracchiolla
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- Francesca Farina
- IRCCS Ospedale San Raffaele
- Emanuele Ammatuna
- University Medical Center Groningen
- Antonella Cingolani
- Dipartimento Di Sicurezza E Bioetica, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS
- Daniel García-Bordallo
- Hospital Universitario Lucus Augusti
- Stefanie K. Gräfe
- Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne
- Yavuz M. Bilgin
- Department of Internal Medicine, ADRZ
- Michelina Dargenio
- Hematology and Stem Cell Transplan Unit, Vito Fazzi
- Tomás José González-López
- Department of Hematology, Hospital Universitario de Burgos
- Anna Guidetti
- University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori
- Tobias Lahmer
- Medizinische Klinik II, Klinikum Rechts Der Isar, TU München
- Esperanza Lavilla-Rubira
- Hospital Universitario Lucus Augusti
- Gustavo-Adolfo Méndez
- Hospital Escuela de Agudos Dr. Ramón Madariaga
- Lucia Prezioso
- Hospital University of Parma - Hematology and Bone Marrow Unit
- Martin Schönlein
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf
- Jaap Van Doesum
- University Medical Center Groningen
- Dominik Wolf
- Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck (MUI)
- Ditte Stampe Hersby
- Department of Hematology, Copenhagen University Hospital - Rigshospitalet
- Ferenc Magyari
- Division of Haematology, Institution of Internal Medicine, Faculty of Medicine, University of Debrecen
- Jens Van Praet
- Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV
- Verena Petzer
- Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck (MUI)
- Carlo Tascini
- Azienda Sanitaria Universitaria del Friuli Centrale
- Iker Falces-Romero
- La Paz University Hospital
- Andreas Glenthøj
- Department of Hematology, Copenhagen University Hospital - Rigshospitalet
- Oliver A. Cornely
- Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne
- Livio Pagano
- Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS
- DOI
- https://doi.org/10.1186/s13045-023-01423-7
- Journal volume & issue
-
Vol. 16,
no. 1
pp. 1 – 5
Abstract
Abstract Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
Keywords